Back to top

The current mutation

ID: V5011
DNA: 7G>T
Protein: E3*
Position: 27762








COV2Var annotation categories







Summary information of mutation (7G>T)

Basic Information about Mutation.

  Gene Information   Gene ID   GU280_gp08
  Gene Name   ORF7b
  Gene Type   protein_coding
  Genome position   27762
  Reference genome   GenBank ID: NC_045512.2
  Mutation type   stop_gained
  DNA Level   DNA Mutation: 7G>T
  Ref Seq: G
  Mut Seq: T
  Protein Level   Protein 1-letter Mutation: E3*
  Protein 3-letter Mutation: Glu3*

Overview of the genomic positions of Mutation.
Note: The annotated 12 genes were retrieved from GeneBank (Accession: NC_045512.2). "MP" represents genomic position of mutation.





Analyzing the distribution of mutation (7G>T) across geographic regions, temporal trends, and lineages

The count of genome sequences harboring this mutation and its distribution across global regions offer insights into regional variations.
Note: The distribution of mutation across 218 geographical regions. Color representation of genome sequence counts. The data is obtained from GISAID's metadata, specifically capturing the regional distribution of genomic sequences.



The dynamic count of genome sequences containing this mutation over time.
Note: Clicking the "Count" or "Cumulative Count" button toggles the view. Count represents the number of genome sequences per month. Cumulative count represents the accumulated total count up to the respective month. The data is obtained from GISAID's metadata, specifically capturing the collection date of genomic sequences.



For every time point represented in the graph above, identifying the top 3 lineages with the highest count of genome sequences carrying this mutation aids in pinpointing noteworthy lineages for further analysis.
Note: Users can filter the lineages by entering a "Year-Month" term in the search box. For example, entering 2020-01 will display lineages that appeared in January 2020. The data is obtained from GISAID's metadata, specifically capturing the collection date of genomic sequences.

Collection date Lineage Total lineage monthly counts Lineage-specific monthly counts Lineage-specific monthly frequency
2020-10 B.1.362.2 57 33 5.79e-1
2020-10 B.1.1.50 57 8 1.40e-1
2020-10 B.1.177.51 57 4 7.02e-2
2020-11 B.1.362.2 93 51 5.48e-1
2020-11 B.1.177.51 93 12 1.29e-1
2020-11 B.1.1.298 93 6 6.45e-2
2020-12 B.1.2 72 31 4.31e-1
2020-12 B.1.1.7 72 8 1.11e-1
2020-12 B.1.177.51 72 6 8.33e-2
2020-03 B.1.1 1 1 1.00e+0
2020-04 B.1 6 3 5.00e-1
2020-04 A.1 6 1 1.67e-1
2020-04 B.1.1 6 1 1.67e-1
2020-05 B.1 4 2 5.00e-1
2020-05 B.1.1.369 4 2 5.00e-1
2020-06 B.1.1.28 7 2 2.86e-1
2020-06 B.1.1 7 1 1.43e-1
2020-06 B.1.1.369 7 1 1.43e-1
2020-07 B.1.218 6 3 5.00e-1
2020-07 B.1 6 1 1.67e-1
2020-07 B.1.240 6 1 1.67e-1
2020-08 B.1.1.419 6 2 3.33e-1
2020-08 B.1.36 6 2 3.33e-1
2020-08 B.1.1.28 6 1 1.67e-1
2020-09 B.1.362.2 18 14 7.78e-1
2020-09 B.1.1.70 18 1 5.56e-2
2020-09 B.1.177 18 1 5.56e-2
2021-01 B.1.2 88 25 2.84e-1
2021-01 B.1.243 88 15 1.70e-1
2021-01 B.1.1.7 88 9 1.02e-1
2021-10 AY.123 455 193 4.24e-1
2021-10 AY.4 455 68 1.49e-1
2021-10 AY.123.1 455 66 1.45e-1
2021-11 AY.123 1087 510 4.69e-1
2021-11 AY.123.1 1087 310 2.85e-1
2021-11 BA.1.21 1087 97 8.92e-2
2021-12 BA.1.21 3478 2143 6.16e-1
2021-12 AY.123 3478 481 1.38e-1
2021-12 AY.123.1 3478 418 1.20e-1
2021-02 B.1.2 69 21 3.04e-1
2021-02 B.1.1.7 69 15 2.17e-1
2021-02 B.1.243 69 6 8.70e-2
2021-03 B.1.1.7 107 51 4.77e-1
2021-03 B.1.351 107 16 1.50e-1
2021-03 B.1.2 107 10 9.35e-2
2021-04 B.1.1.7 155 114 7.35e-1
2021-04 B.1.351 155 16 1.03e-1
2021-04 B.1.621 155 4 2.58e-2
2021-05 B.1.1.7 245 173 7.06e-1
2021-05 B.1.621 245 24 9.80e-2
2021-05 B.1.429 245 11 4.49e-2
2021-06 B.1.621 121 50 4.13e-1
2021-06 B.1.1.7 121 39 3.22e-1
2021-06 P.1 121 8 6.61e-2
2021-07 B.1.621 118 65 5.51e-1
2021-07 B.1.1.7 118 16 1.36e-1
2021-07 P.1 118 13 1.10e-1
2021-08 B.1.621 125 51 4.08e-1
2021-08 AY.123 125 14 1.12e-1
2021-08 AY.43 125 9 7.20e-2
2021-09 AY.123 236 116 4.92e-1
2021-09 B.1.621 236 32 1.36e-1
2021-09 AY.4 236 19 8.05e-2
2022-01 BA.1.21 3388 2582 7.62e-1
2022-01 BA.1.21.1 3388 458 1.35e-1
2022-01 BA.1.1 3388 157 4.63e-2
2022-10 BF.7 55 37 6.73e-1
2022-10 BF.26 55 3 5.45e-2
2022-10 BQ.1 55 3 5.45e-2
2022-11 BF.7 71 47 6.62e-1
2022-11 BF.5 71 7 9.86e-2
2022-11 BA.5.1.1 71 2 2.82e-2
2022-12 BF.7 53 25 4.72e-1
2022-12 BF.5 53 6 1.13e-1
2022-12 BQ.1.1 53 4 7.55e-2
2022-02 BA.1.21 1746 1155 6.62e-1
2022-02 BA.1.21.1 1746 332 1.90e-1
2022-02 BA.1.1 1746 148 8.48e-2
2022-03 BA.1.21 536 307 5.73e-1
2022-03 BA.2 536 87 1.62e-1
2022-03 BA.1.21.1 536 56 1.04e-1
2022-04 BA.2 157 78 4.97e-1
2022-04 BA.1.21.1 157 25 1.59e-1
2022-04 BA.1.21 157 21 1.34e-1
2022-05 BA.2 96 62 6.46e-1
2022-05 BA.2.9 96 8 8.33e-2
2022-05 BA.2.12 96 6 6.25e-2
2022-06 BA.2 95 40 4.21e-1
2022-06 BA.2.54 95 27 2.84e-1
2022-06 BA.2.9 95 6 6.32e-2
2022-07 BA.2 60 8 1.33e-1
2022-07 BA.2.54 60 8 1.33e-1
2022-07 BA.2.3 60 6 1.00e-1
2022-08 BA.5 36 4 1.11e-1
2022-08 BA.5.2.9 36 3 8.33e-2
2022-08 BA.5.3.1 36 3 8.33e-2
2022-09 BF.7 30 13 4.33e-1
2022-09 BA.5.9 30 3 1.00e-1
2022-09 BA.5.3.1 30 2 6.67e-2
2023-01 BF.7 30 13 4.33e-1
2023-01 XBB.1.5 30 6 2.00e-1
2023-01 BN.1.2 30 2 6.67e-2
2023-02 XBB.1.5 50 47 9.40e-1
2023-02 BF.7 50 1 2.00e-2
2023-02 BQ.1.1 50 1 2.00e-2

The count of genome sequences and the frequency of this mutation in each lineage.
Note: Displaying mutation frequencies (>0.01) among 2,735 lineages. Mutation Count represents the count of sequences carrying this mutation. Users can filter the lineages by entering a search term in the search box. For example, entering "A.1" will display A.1 lineages. The data is obtained from GISAID's metadata, specifically capturing the lineage of genomic sequences. Mutation count: Count of sequences carrying this mutation.

Mutation ID Lineage Mutation frequency Mutation count Earliest lineage emergence Latest lineage emergence
V5011 AY.123 7.99e-1 1350 2021-3-9 2022-3-17
V5011 AY.123.1 9.72e-1 413 2021-1-12 2022-1-26
V5011 B.1.177.51 1.44e-1 32 2020-10-1 2021-4-20
V5011 B.1.218 1.55e-2 3 2020-7-20 2021-11-22
V5011 B.1.362.2 4.90e-1 103 2020-9-1 2021-2-2
V5011 B.1.621 2.05e-2 236 2020-5-7 2022-1-25
V5011 B.1.78 2.80e-2 3 2020-3-12 2021-12-9
V5011 BA.1.21 9.81e-1 6316 2021-2-21 2022-12-14
V5011 BA.1.21.1 9.78e-1 1005 2021-10-11 2022-6-28
V5011 BA.2.54 4.10e-2 35 2021-11-15 2022-10-28
V5011 XAD 6.80e-2 7 2022-2-7 2022-8-4






Examining mutation (7G>T) found in abundant sequences of non-human animal hosts

Exploring mutation presence across 35 non-human animal hosts for cross-species transmission.
Note: We retained the mutation that appear in at least three non-human animal hosts' sequences. The data is obtained from GISAID's metadata, specifically capturing the host of genomic sequences.

Animal host Lineage Source region Collection date Accession ID




Association between mutation (7G>T) and patients of different ages, genders, and statuses

Note: The logistic regression model was employed to examine changes in patient data before and after the mutation. The logistic regression model was conducted using the glm function in R. The data is obtained from GISAID's metadata, specifically capturing the patient status, gender, and age of genomic sequences.

Analyzing the association between mutation and patient status.
Note: we categorized the data into different patient statuses (ambulatory, deceased, homebound, hospitalized, mild, and recovered) based on GISAID classifications. In the analysis exploring the association between mutation and patient status, the model included mutation, patient status, patient age, gender, sequence region of origin, and sequence collection time point. In the 'increase' direction of the mutation, it means that when this mutation occurs, it increases the corresponding effect proportion. In the 'decrease' direction of the mutation, it means that when this mutation occurs, it decreases the corresponding effect proportion. A p-value lower than 0.001 signifies a notable differentiation between the population with and without the mutation.

Attribute Effect Estimate SE Z-value P-value Direction
Patient status Ambulatory 2.78e+0 5.43e-1 5.12e+0 3.13e-7 Increase
Deceased -1.59e+1 4.64e+2 -3.41e-2 9.73e-1 Decrease
Homebound -1.79e-15 4.95e+4 -3.60e-20 1.00e+0 Decrease
Hospitalized 1.06e+0 3.13e-1 3.38e+0 7.36e-4 Increase
Mild 2.56e-1 5.30e-1 4.83e-1 6.29e-1 Increase
Recovered -2.65e+0 3.63e-1 -7.30e+0 2.79e-13 Decrease

Analyzing the association between mutation and patient status.
Note: we categorized the data into different patient age (0-17, 18-39, 40-64, 65-84, and 85+). In the analysis exploring the association between mutation and patient age, the model included mutation, patient age, gender, sequence region of origin, and sequence collection time point. In the 'increase' direction of the mutation, it means that when this mutation occurs, it increases the corresponding effect proportion. In the 'decrease' direction of the mutation, it means that when this mutation occurs, it decreases the corresponding effect proportion. A p-value lower than 0.001 signifies a notable differentiation between the population with and without the mutation.

Attribute Effect Estimate SE Z-value P-value Direction
Patient age, years 0-17 2.49e-1 1.08e-1 2.31e+0 2.11e-2 Increase
18-39 1.75e-1 6.12e-2 2.86e+0 4.25e-3 Increase
40-64 5.42e-2 6.13e-2 8.83e-1 3.77e-1 Increase
65-84 -4.12e-1 8.00e-2 -5.15e+0 2.60e-7 Decrease
>=85 -2.84e-1 1.31e-1 -2.16e+0 3.06e-2 Decrease

Analyzing the association between mutation and patient status.
Note: we categorized the data into different patient gender (male and female). In the analysis exploring the association between mutation and patient gender, the model included mutation, patient gender, patient age, sequence region of origin, and sequence collection time point. In the 'increase' direction of the mutation, it means that when this mutation occurs, it increases the corresponding effect proportion. In the 'decrease' direction of the mutation, it means that when this mutation occurs, it decreases the corresponding effect proportion. A p-value lower than 0.001 signifies a notable differentiation between the population with and without the mutation.

Attribute Effect Estimate SE Z-value P-value Direction
Patient gender Male -4.65e-2 5.84e-2 -7.97e-1 4.25e-1 Decrease





Investigating natural selection at mutation (7G>T) site for genetic adaptation and diversity

Note: Investigating the occurrence of positive selection or negative selection at this mutation site reveals implications for genetic adaptation and diversity.

The MEME method within the HyPhy software was employed to analyze positive selection. MEME: episodic selection.
Note: List of sites found to be under episodic selection by MEME (p < 0.05). "Protein Start" corresponds to the protein's starting genomic position. "Protein End" corresponds to the protein's ending genomic position. The term 'site' represents a selection site within the protein.

Protein name Protein start Protein end Protein length Site P-value Lineage Method

The FEL method within the HyPhy software was employed to analyze both positive and negative selection. FEL: pervasive selection on samll datasets.
Note: List of sites found to be under pervasive selection by FEL (p < 0.05). A beta value greater than alpha signifies positive selection, while a beta value smaller than alpha signifies negative selection. "Protein Start" corresponds to the protein's starting genomic position. "Protein End" corresponds to the protein's ending genomic position. The term 'site' represents a selection site within the protein.

Protein name Protein start Protein end Protein length Site Alpha Beta P-value Lineage Method

The FUBAR method within the HyPhy software was employed to analyze both positive and negative selection. FUBAR: pervasive selection on large datasets.
Note: List of sites found to be under pervasive selection by FUBAR (prob > 0.95). A prob[alpha < beta] value exceeding 0.95 indicates positive selection, while a prob[alpha > beta] value exceeding 0.95 indicates negative selection. "Protein Start" corresponds to the protein's starting genomic position. "Protein End" corresponds to the protein's ending genomic position. The term 'site' represents a selection site within the protein.

Protein name Protein start Protein end Protein length Site Prob[alpha>beta] Prob[alpha<beta] Lineage Method




Alterations in protein physicochemical properties induced by mutation (7G>T)

Understanding the alterations in protein physicochemical properties can reveal the evolutionary processes and adaptive changes of viruses
Note: ProtParam software was used for the analysis of physicochemical properties. Significant change threshold: A change exceeding 10% compared to the reference is considered a significant change. "GRAVY" is an abbreviation for "grand average of hydropathicity".

Group Protein name Molecular weight Theoretical PI Extinction coefficients Aliphatic index GRAVY




Alterations in protein stability induced by mutation (7G>T)

The impact of mutations on protein stability directly or indirectly affects the biological characteristics, adaptability, and transmission capacity of the virus
Note: iMutant 2.0 was utilized to analyze the effects of mutations on protein stability. pH 7 and a temperature of 25°C are employed to replicate the in vitro environment. pH 7.4 and a temperature of 37°C are utilized to simulate the in vivo environment.

Mutation Protein name Mutation type Position ΔDDG Stability pH Temperature Condition




Impact on protein function induced by mutation (7G>T)

The impact of mutations on protein function
Note: The MutPred2 software was used to predict the pathogenicity of a mutation and gives the molecular mechanism of pathogenicity. A score above 0.5 indicates an increased likelihood of pathogenicity. "Pr" is the abbreviation for "proportion. P" is the abbreviation for "p-value.

Mutation Protein name Mutation type Score Molecular mechanisms




Exploring mutation (7G>T) distribution within intrinsically disordered protein regions

Intrinsically Disordered Proteins (IDPs) which refers to protein regions that have no unique 3D structure. In viral proteins, mutations in the disordered regions s are critical for immune evasion and antibody escape, suggesting potential additional implications for vaccines and monoclonal therapeutic strategies.
Note: The iupred3 software was utilized for analyzing IDPs. A score greater than 0.5 is considered indicative of an IDP. In the plot, "POS" represents the position of the mutation.





Alterations in enzyme cleavage sites induced by mutation (7G>T)

Exploring the impact of mutations on the cleavage sites of 28 enzymes.
Note: The PeptideCutter software was used for detecting enzymes cleavage sites. The increased enzymes cleavage sites refer to the cleavage sites in the mutated protein that are added compared to the reference protein. Conversely, the decreased enzymes cleavage sites indicate the cleavage sites in the mutated protein that are reduced compared to the reference protein.

Mutation Protein name Genome position Enzyme name Increased cleavage sites Decreased cleavage sites




Impact of spike protein mutation (7G>T) on antigenicity and immunogenicity

Investigating the impact of mutations on antigenicity and immunogenicity carries important implications for vaccine design and our understanding of immune responses.
Note: An absolute change greater than 0.0102 (three times the median across sites) in antigenicity score is considered significant. An absolute changegreater than 0.2754 (three times the median across sites) in immunogenicity score is considered significant. The VaxiJen tool was utilized for antigenicity analysis. The IEDB tool was used for immunogenicity analysis. Antigens with a prediction score of more than 0.4 for this tool are considered candidate antigens. MHC I immunogenicity score >0, indicating a higher probability to stimulate an immune response.

Group Protein name Protein region Antigenicity score Immunogenicity score




Impact of mutation (7G>T) on viral transmissibility by the affinity between RBD and ACE2 receptor

Unraveling the impact of mutations on the interaction between the receptor binding domain (RBD) and ACE2 receptor using deep mutational scanning (DMS) experimental data to gain insights into their effects on viral transmissibility.
Note: The ΔBinding affinity represents the disparity between the binding affinity of a mutation and the reference binding affinity. A positive Δbinding affinity value (Δlog10(KD,app) > 0) signifies an increased affinity between RBD and ACE2 receptor due to the mutation. Conversely, a negative value (Δlog10(KD,app) < 0) indicates a reduced affinity between RBD and ACE2 receptor caused by the mutation. A p-value smaller than 0.05 indicates significance. "Ave mut bind" represents the average binding affinity of this mutation. "Ave ref bind" refers to the average binding affinity at a site without any mutation (reference binding affinity).

;
Mutation Protein name Protein region Mutation Position Ave mut bind Ave ref bind ΔBinding affinity P-value Image


The interface between the receptor binding domain (RBD) and ACE2 receptor is depicted in the crystal structure 6JM0.
Note: The structure 6M0J encompasses the RBD range of 333 to 526. The binding sites (403-406, 408, 417, 439, 445-447, 449, 453, 455-456, 473-478, 484-498, and 500-506) on the RBD that interface with ACE2 are indicated in magenta. The binding sites on the RBD that have been identified through the interface footprints experiment. The ACE2 binding sites within the interface are shown in cyan, representing residues within 5Å proximity to the RBD binding sites. The mutation within the RBD range of 333 to 526 is depicted in red.

        Show as:

        Show interface residues:





Impact of mutation (7G>T) on immune escape by the affinity between RBD and antibody/serum

By utilizing experimental data from deep mutational scanning (DMS), we can uncover how mutations affect the interaction between the receptor binding domain (RBD) and antibodies/serum. This approach provides valuable insights into strategies for evading the host immune response.
Note: We considered a mutation to mediate strong escape if the escape score exceeded 0.1 (10% of the maximum score of 1). A total of 1,504 antibodies/serum data were collected for this analysis. "Condition name" refers to the name of the antibodies/serum. "Mut escape score" represents the escape score of the mutation in that specific condition. "Avg mut escape score" indicates the average escape score of the mutation site in that condition, considering the occurrence of this mutation and other mutations. Class 1 antibodies bind to an epitope only in the RBD “up” conformation, and are the most abundant. Class 2 antibodies bind to the RBD both in “up” and “down” conformations. Class 3 and class 4 antibodies both bind outside the ACE2 binding site. Class 3 antibodies bind the RBD in both the open and closed conformation, while class 4 antibodies bind only in the open conformation.

Mutation Condition name Condition type Condition subtype Condition year Mut escape score Avg mut escape score




Investigating the co-mutation patterns of mutation (7G>T) across 2,735 viral lineages

Investigating the co-mutation patterns of SARS-CoV-2 across 2,735 viral lineages to unravel the cooperative effects of different mutations. In biological research, correlation analysis of mutation sites helps us understand whether there is a close relationship or interaction between certain mutations.
Note: The Spearman correlation coefficient is used to calculate the correlation between two mutations within each Pango lineage. Holm–Bonferroni method was used for multiple test adjustment. We retained mutation pairs with correlation values greater than 0.6 or less than -0.6 and Holm–Bonferroni corrected p-values less than 0.05.

Associated mutation ID DNA mutation Mutation type Protein name Protein mutation correlation coefficient Lineage
V4856 23C>T missense_variant ORF7a A8V 6.05e-1 AY.5
V4932 211G>T missense_variant ORF7a V71L 6.25e-1 AY.20
V1510 6364C>T missense_variant ORF1ab_pp1a L2122F 7.81e-1 AY.4.2
V590 1727A>G missense_variant ORF1ab_pp1a Y576C 6.03e-1 BA.1.15.1
V98 -24G>A upstream_gene_variant ORF1ab_pp1a None 9.35e-1 BA.2.10
V171 224A>G missense_variant ORF1ab_pp1a D75G 7.07e-1 BA.5.6
V6516 4728C>T synonymous_variant ORF1ab_pp1a N1576N 6.61e-1 XBB.1.5
V2696 15188G>T missense_variant ORF1ab_pp1ab G5063V 7.07e-1 A.23.1
V3447 20813C>T missense_variant ORF1ab_pp1ab T6938I 7.07e-1 A.23.1
V3884 1354C>A missense_variant S L452M 1.00e+0 A.23.1
V4434 225G>T missense_variant ORF3a K75N 7.07e-1 A.23.1
V4451 275C>T missense_variant ORF3a S92L 7.07e-1 A.23.1
V5067 10C>T missense_variant ORF8 L4F 7.07e-1 A.23.1
V6102 1708C>T synonymous_variant ORF1ab_pp1a L570L 7.07e-1 A.23.1
V723 2272T>G missense_variant ORF1ab_pp1a L758V 7.07e-1 A.23.1
V7650 13680C>T synonymous_variant ORF1ab_pp1ab N4560N 7.07e-1 A.23.1
V7894 15499C>T synonymous_variant ORF1ab_pp1ab L5167L 1.00e+0 A.23.1
V8491 20136A>G synonymous_variant ORF1ab_pp1ab E6712E 7.07e-1 A.23.1
V8744 870C>T synonymous_variant S D290D 1.00e+0 A.23.1
V8807 1383C>T synonymous_variant S L461L 7.07e-1 A.23.1
V948 3218G>T missense_variant ORF1ab_pp1a G1073V 1.00e+0 A.23.1
V9520 105C>T synonymous_variant ORF8 D35D 7.07e-1 A.23.1
V9561 18C>T synonymous_variant N P6P 8.16e-1 A.23.1
V1828 8507C>T missense_variant ORF1ab_pp1a T2836I 7.07e-1 A.27
V1758 8053C>A missense_variant ORF1ab_pp1a P2685T 7.74e-1 AY.106
V3909 1450G>A missense_variant S E484K 8.66e-1 AY.106
V6774 6676C>T synonymous_variant ORF1ab_pp1a L2226L 1.00e+0 AY.106
V8394 19251A>G synonymous_variant ORF1ab_pp1ab R6417R 1.00e+0 AY.106
V2968 17526G>T missense_variant ORF1ab_pp1ab Q5842H 1.00e+0 AY.110
V313 632C>T missense_variant ORF1ab_pp1a A211V 1.00e+0 AY.110
V4294 3788C>T missense_variant S P1263L 1.00e+0 AY.110
V7414 11760C>T synonymous_variant ORF1ab_pp1a S3920S 1.00e+0 AY.110
V8564 20793C>T synonymous_variant ORF1ab_pp1ab D6931D 1.00e+0 AY.110
V1246 4828C>T missense_variant ORF1ab_pp1a H1610Y 8.16e-1 AY.113
V6147 1998C>A synonymous_variant ORF1ab_pp1a T666T 7.07e-1 AY.113
V5157 197G>A missense_variant ORF8 G66D 1.00e+0 AY.114
V8998 2856C>T synonymous_variant S V952V 1.00e+0 AY.114
V8121 17202A>G synonymous_variant ORF1ab_pp1ab T5734T 7.07e-1 AY.120
V1334 5465C>T missense_variant ORF1ab_pp1a T1822I 7.79e-1 AY.123
V2968 17526G>T missense_variant ORF1ab_pp1ab Q5842H 8.00e-1 AY.123
V313 632C>T missense_variant ORF1ab_pp1a A211V 7.98e-1 AY.123
V4294 3788C>T missense_variant S P1263L 7.34e-1 AY.123
V9572 63A>T synonymous_variant N S21S 1.00e+0 AY.134
V8064 16815G>A synonymous_variant ORF1ab_pp1ab Q5605Q 7.07e-1 AY.14
V6746 6399C>T synonymous_variant ORF1ab_pp1a V2133V 6.06e-1 AY.23
V2175 11065G>A missense_variant ORF1ab_pp1a V3689I 1.00e+0 AY.25.3
V8983 2763A>G synonymous_variant S K921K 6.32e-1 AY.36
V1914 9124G>A missense_variant ORF1ab_pp1a D3042N 8.16e-1 AY.46.4
V4738 138G>T missense_variant M L46F 8.16e-1 AY.46.4
V3022 17911C>T missense_variant ORF1ab_pp1ab P5971S 9.54e-1 AY.46.6
V7376 11517A>G synonymous_variant ORF1ab_pp1a K3839K 7.80e-1 AY.46.6
V3201 19079C>T missense_variant ORF1ab_pp1ab A6360V 1.00e+0 AY.46
V1948 9400C>T missense_variant ORF1ab_pp1a P3134S 1.00e+0 AY.4.7
V4106 2562G>T missense_variant S K854N 7.07e-1 AY.4.7
V2638 14593G>T missense_variant ORF1ab_pp1ab V4865F 7.07e-1 AY.54
V3491 21070G>T missense_variant ORF1ab_pp1ab A7024S 6.55e-1 AY.54
V6453 4275C>T synonymous_variant ORF1ab_pp1a Y1425Y 8.66e-1 AY.54
V6482 4458T>C synonymous_variant ORF1ab_pp1a Y1486Y 1.00e+0 AY.54
V6496 4611C>T synonymous_variant ORF1ab_pp1a Y1537Y 8.66e-1 AY.54
V8522 20439C>T synonymous_variant ORF1ab_pp1ab Y6813Y 7.75e-1 AY.54
V979 3322C>T missense_variant ORF1ab_pp1a H1108Y 8.66e-1 AY.54
V8644 174C>T synonymous_variant S F58F 1.00e+0 AY.59
V2124 10855A>G missense_variant ORF1ab_pp1a I3619V 6.32e-1 AY.79
V4669 61C>T missense_variant E L21F 7.07e-1 AY.79
V5784 *4367_*4378delGATCGAGTGTAC downstream_gene_variant S None 7.07e-1 AY.79
V6771 6631C>T synonymous_variant ORF1ab_pp1a L2211L 1.00e+0 AY.93
V6875 7554C>T synonymous_variant ORF1ab_pp1a L2518L 7.07e-1 B.1.1.207
V9035 3186C>T synonymous_variant S F1062F 1.00e+0 B.1.1.207
V7183 9885T>C synonymous_variant ORF1ab_pp1a L3295L 1.00e+0 B.1.1.222
V1158 4312C>T missense_variant ORF1ab_pp1a L1438F 6.09e-1 B.1.1.232
V1260 4913C>T missense_variant ORF1ab_pp1a T1638I 6.09e-1 B.1.1.232
V2697 15257T>A missense_variant ORF1ab_pp1ab F5086Y 6.65e-1 B.1.1.232
V3018 17903C>T missense_variant ORF1ab_pp1ab P5968L 6.09e-1 B.1.1.232
V3556 80C>T missense_variant S A27V 6.52e-1 B.1.1.232
V3870 1331A>G missense_variant S K444R 7.05e-1 B.1.1.232
V471 1293A>G missense_variant ORF1ab_pp1a I431M 6.52e-1 B.1.1.232
V5242 -2A>G upstream_gene_variant N None 6.09e-1 B.1.1.232
V5647 1226A>T missense_variant N Q409L 7.05e-1 B.1.1.232
V7560 12942C>T synonymous_variant ORF1ab_pp1a A4314A 6.09e-1 B.1.1.232
V768 2482G>T missense_variant ORF1ab_pp1a D828Y 6.52e-1 B.1.1.232
V7923 15693G>T synonymous_variant ORF1ab_pp1ab G5231G 6.09e-1 B.1.1.232
V9145 81T>C synonymous_variant ORF3a D27D 6.09e-1 B.1.1.232
V2078 10568C>T missense_variant ORF1ab_pp1a A3523V 6.92e-1 B.1.1.28
V4566 579G>T missense_variant ORF3a W193C 8.56e-1 B.1.1.28
V8662 249C>T synonymous_variant S V83V 7.32e-1 B.1.1.28
V2639 14610G>T missense_variant ORF1ab_pp1ab K4870N 7.07e-1 B.1.1.294
V4519 439C>T missense_variant ORF3a L147F 1.00e+0 B.1.1.294
V6231 2538T>C synonymous_variant ORF1ab_pp1a D846D 1.00e+0 B.1.1.294
V6507 4662C>T synonymous_variant ORF1ab_pp1a D1554D 1.00e+0 B.1.1.294
V6880 7579C>T synonymous_variant ORF1ab_pp1a L2527L 1.00e+0 B.1.1.294
V7169 9771C>T synonymous_variant ORF1ab_pp1a I3257I 1.00e+0 B.1.1.294
V8584 20955C>T synonymous_variant ORF1ab_pp1ab F6985F 1.00e+0 B.1.1.294
V403 1037C>T missense_variant ORF1ab_pp1a T346I 7.07e-1 B.1.1.317
V4441 249G>T missense_variant ORF3a L83F 1.00e+0 B.1.1.317
V4456 285G>T missense_variant ORF3a L95F 7.07e-1 B.1.1.317
V5574 974C>T missense_variant N T325I 7.07e-1 B.1.1.317
V6333 3282T>C synonymous_variant ORF1ab_pp1a N1094N 8.16e-1 B.1.1.317
V739 2327C>T missense_variant ORF1ab_pp1a A776V 7.07e-1 B.1.1.317
V7685 13923G>A synonymous_variant ORF1ab_pp1ab R4641R 1.00e+0 B.1.1.317
V7886 15420T>C synonymous_variant ORF1ab_pp1ab Y5140Y 1.00e+0 B.1.1.317
V281 496A>G missense_variant ORF1ab_pp1a S166G 8.16e-1 B.1.1.348
V439 1172C>T missense_variant ORF1ab_pp1a S391F 8.16e-1 B.1.1.348
V5812 *4393G>T downstream_gene_variant S None 7.07e-1 B.1.1.348
V2995 17764G>T missense_variant ORF1ab_pp1ab A5922S 8.66e-1 B.1.1.369
V4312 37G>T missense_variant ORF3a V13L 8.66e-1 B.1.1.369
V1101 3848C>T missense_variant ORF1ab_pp1a A1283V 8.24e-1 B.1.1.50
V6984 8418C>T synonymous_variant ORF1ab_pp1a I2806I 8.94e-1 B.1.1.50
V8771 1110T>C synonymous_variant S N370N 9.35e-1 B.1.1.50
V9076 3438C>T synonymous_variant S D1146D 9.42e-1 B.1.1.50
V7478 12228C>T synonymous_variant ORF1ab_pp1a D4076D 1.00e+0 B.1.1.70
V9295 79C>T synonymous_variant M L27L 1.00e+0 B.1.1.70
V9494 49C>T synonymous_variant ORF7b L17L 1.00e+0 B.1.1.70
V3969 1841A>G missense_variant S D614G -7.07e-1 B.1.177.43
V8449 19719C>T synonymous_variant ORF1ab_pp1ab V6573V 1.00e+0 B.1.177.43
V8948 2490T>C synonymous_variant S D830D 9.49e-1 B.1.177.81
V5174 226A>G missense_variant ORF8 I76V 9.13e-1 B.1.221
V9764 981G>T synonymous_variant N S327S 6.74e-1 B.1.221
V9779 1059G>T synonymous_variant N L353L 7.07e-1 B.1.234
V7678 13857A>G synonymous_variant ORF1ab_pp1ab P4619P 8.36e-1 B.1.243
V3751 725_733delTTGCTTTAC disruptive_inframe_deletion S L242_L244del 1.00e+0 B.1.258.3
V3831 1062C>A missense_variant S N354K 7.06e-1 B.1.258.3
V3847 1151C>T missense_variant S P384L 7.06e-1 B.1.258.3
V3907 1447G>T missense_variant S V483F 1.00e+0 B.1.258.3
V4151 3017C>T missense_variant S T1006I 7.06e-1 B.1.258.3
V8846 1719T>C synonymous_variant S T573T 7.06e-1 B.1.258.3
V3508 21204G>T missense_variant ORF1ab_pp1ab M7068I 7.66e-1 B.1.351
V5198 308C>T missense_variant ORF8 S103L 8.74e-1 B.1.351
V5286 61T>C missense_variant N S21P 7.21e-1 B.1.351
V7619 13341C>T synonymous_variant ORF1ab_pp1ab R4447R 6.97e-1 B.1.351
V7550 12850C>T synonymous_variant ORF1ab_pp1a L4284L 1.00e+0 B.1.36.8
V4300 3802G>A missense_variant S V1268I 1.00e+0 B.1.428
V4424 201G>T missense_variant ORF3a K67N 1.00e+0 B.1.428
V8466 19884C>T synonymous_variant ORF1ab_pp1ab F6628F 1.00e+0 B.1.428
V9339 354T>C synonymous_variant M I118I 1.00e+0 B.1.428
V2062 10463C>T missense_variant ORF1ab_pp1a T3488I 7.07e-1 B.1.436
V2539 13766G>A missense_variant ORF1ab_pp1ab R4589Q 1.00e+0 B.1.436
V3445 20794C>T missense_variant ORF1ab_pp1ab P6932S 1.00e+0 B.1.436
V4510 400C>T missense_variant ORF3a R134C 7.07e-1 B.1.436
V5916 418C>T synonymous_variant ORF1ab_pp1a L140L 7.07e-1 B.1.436
V8680 349C>T synonymous_variant S L117L 7.07e-1 B.1.436
V8985 2775C>T synonymous_variant S N925N 1.00e+0 B.1.436
V1974 9659C>T missense_variant ORF1ab_pp1a A3220V 7.07e-1 B.1.466.2
V3946 1674G>T missense_variant S K558N 7.07e-1 B.1.466.2
V6505 4653C>T synonymous_variant ORF1ab_pp1a I1551I 7.07e-1 B.1.466.2
V562 1649G>A missense_variant ORF1ab_pp1a R550H 8.16e-1 B.1.470
V3344 20125C>T missense_variant ORF1ab_pp1ab R6709C 1.00e+0 B.1.588
V5002 361G>T stop_gained ORF7a E121* 7.07e-1 B.1.588
V7918 15675T>C synonymous_variant ORF1ab_pp1ab D5225D 1.00e+0 B.1.588
V1263 4919C>T missense_variant ORF1ab_pp1a P1640L 1.00e+0 B.1.619
V1863 8672C>T missense_variant ORF1ab_pp1a A2891V 1.00e+0 B.1.619
V2317 12047C>T missense_variant ORF1ab_pp1a A4016V 1.00e+0 B.1.619
V4438 232C>T missense_variant ORF3a H78Y 1.00e+0 B.1.619
V5357 268G>T missense_variant N A90S 1.00e+0 B.1.619
V676 2040G>T missense_variant ORF1ab_pp1a K680N 1.00e+0 B.1.619
V8994 2820C>T synonymous_variant S S940S 1.00e+0 B.1.619
V2277 11788C>T missense_variant ORF1ab_pp1a L3930F 1.00e+0 B.1.620
V6871 7512C>T synonymous_variant ORF1ab_pp1a Y2504Y 1.00e+0 B.1.620
V7645 13623C>T synonymous_variant ORF1ab_pp1ab Y4541Y 1.00e+0 B.1.620
V9645 435C>T synonymous_variant N H145H 1.00e+0 B.1.620
V181 245_259delGTCATGTTATGGTTG disruptive_inframe_deletion ORF1ab_pp1a G82_V86del 7.40e-1 B.1.621
V4273 3711G>T missense_variant S M1237I 9.06e-1 B.1.621
V7564 12960C>T synonymous_variant ORF1ab_pp1a S4320S 6.33e-1 B.1.621
V8260 18222C>T synonymous_variant ORF1ab_pp1ab L6074L 6.11e-1 B.1.621
V3371 20216C>T missense_variant ORF1ab_pp1ab S6739L 7.07e-1 BA.1.1.10
V5384 409G>A missense_variant N G137R 1.00e+0 BA.1.1.10
V6221 2451C>T synonymous_variant ORF1ab_pp1a G817G 1.00e+0 BA.1.1.10
V7323 11109T>C synonymous_variant ORF1ab_pp1a D3703D 7.07e-1 BA.1.1.10
V9685 624T>C synonymous_variant N A208A 1.00e+0 BA.1.1.11
V8879 1965T>C synonymous_variant S H655H 1.00e+0 BA.2.10.1
V7799 14673C>T synonymous_variant ORF1ab_pp1ab D4891D 9.13e-1 BA.2.12
V1995 9886G>T missense_variant ORF1ab_pp1a D3296Y 1.00e+0 BA.2.21
V3031 17961G>T missense_variant ORF1ab_pp1ab M5987I 7.07e-1 BA.2.36
V807 2677C>A missense_variant ORF1ab_pp1a L893M 7.07e-1 BA.2.38
V8636 129C>T synonymous_variant S F43F 7.07e-1 BA.2.38
V4622 766_768delGTT conservative_inframe_deletion ORF3a V256del 1.00e+0 BA.2.3.9
V603 1772C>T missense_variant ORF1ab_pp1a A591V 1.00e+0 BA.2.3.9
V5417 533G>T missense_variant N G178V 9.39e-1 BA.2.54
V2990 17735C>T missense_variant ORF1ab_pp1ab T5912I 8.65e-1 BA.2.62
V9261 18G>A synonymous_variant E S6S 8.65e-1 BA.2.62
V1019 3476T>C missense_variant ORF1ab_pp1a I1159T 1.00e+0 BA.2.65
V8691 435C>T synonymous_variant S Y145Y 7.07e-1 BA.2.65
V8969 2619C>T synonymous_variant S Y873Y 1.00e+0 BA.2.65
V8284 18423C>T synonymous_variant ORF1ab_pp1ab C6141C 7.07e-1 BA.5.1.24
V3138 18664C>T missense_variant ORF1ab_pp1ab P6222S 6.32e-1 BA.5.1.30
V5446 584G>T missense_variant N R195I 1.00e+0 BA.5.3.3
V5592 1069A>G missense_variant N I357V 8.66e-1 BA.5.3.3
V7190 9921C>T synonymous_variant ORF1ab_pp1a C3307C 6.12e-1 BA.5.9
V7691 13956C>T synonymous_variant ORF1ab_pp1ab D4652D 7.07e-1 BA.5.9
V7959 15996C>T synonymous_variant ORF1ab_pp1ab C5332C 7.75e-1 BA.5.9
V4367 121C>T missense_variant ORF3a L41F 1.00e+0 BE.4
V451 1204C>T missense_variant ORF1ab_pp1a R402C 7.07e-1 BF.21
V6352 3423C>T synonymous_variant ORF1ab_pp1a H1141H 7.07e-1 BF.21
V157 161_163delTAG disruptive_inframe_deletion ORF1ab_pp1a V54del 1.00e+0 BF.2
V273 448G>A missense_variant ORF1ab_pp1a G150S 7.07e-1 BF.3
V2958 17470C>T missense_variant ORF1ab_pp1ab L5824F 7.07e-1 BF.3
V3882 1348A>G missense_variant S N450D 7.07e-1 BF.3
V5673 -6A>G upstream_gene_variant ORF10 None 7.07e-1 BF.3
V6185 2229G>A synonymous_variant ORF1ab_pp1a E743E 7.07e-1 BF.3
V5885 264G>A synonymous_variant ORF1ab_pp1a L88L 7.07e-1 BF.4
V9438 120C>T synonymous_variant ORF7a Y40Y 7.07e-1 BF.4
V53 -80C>T upstream_gene_variant ORF1ab_pp1a None 1.00e+0 BF.6
V6846 7299C>T synonymous_variant ORF1ab_pp1a S2433S 1.00e+0 BF.7.8
V4004 2008A>G missense_variant S I670V 8.16e-1 BF.8
V2653 14762C>T missense_variant ORF1ab_pp1ab A4921V 1.00e+0 BN.1
V4955 251C>T missense_variant ORF7a P84L 1.00e+0 BN.1
V7767 14469A>G synonymous_variant ORF1ab_pp1ab E4823E 1.00e+0 BN.1
V703 2193G>T missense_variant ORF1ab_pp1a M731I 1.00e+0 BQ.1.1.18
V703 2193G>T missense_variant ORF1ab_pp1a M731I 1.00e+0 BQ.1.1.3
V8624 33C>T synonymous_variant S V11V 1.00e+0 BQ.1.1.3
V9287 15C>T synonymous_variant M N5N 1.00e+0 BQ.1.1.3
V5691 23C>T missense_variant ORF10 A8V 1.00e+0 BQ.1.1.7
V3554 79G>A missense_variant S A27T 7.07e-1 C.35
V5576 980C>T missense_variant N S327L 7.07e-1 C.35
V5227 359T>C missense_variant ORF8 F120S 1.00e+0 CH.1.1
V7035 8808C>T synonymous_variant ORF1ab_pp1a T2936T 1.00e+0 CH.1.1
V6209 2394G>A synonymous_variant ORF1ab_pp1a K798K 7.07e-1 P.1.10
V7820 14880T>C synonymous_variant ORF1ab_pp1ab N4960N 1.00e+0 P.1.10
V7610 13272C>T synonymous_variant ORF1ab_pp1ab Y4424Y 8.16e-1 R.1
V6739 6363C>T synonymous_variant ORF1ab_pp1a T2121T 7.07e-1 XBF
V92 -33C>T upstream_gene_variant ORF1ab_pp1a None 1.00e+0 XBF
V2744 15718G>A missense_variant ORF1ab_pp1ab V5240I 1.00e+0 XB
V4952 245T>C missense_variant ORF7a V82A 8.67e-1 AY.123.1
V5000 359C>T missense_variant ORF7a T120I 1.00e+0 AY.123.1
V1683 7592A>G missense_variant ORF1ab_pp1a N2531S 1.00e+0 B.1.1.265
V3235 19402G>T missense_variant ORF1ab_pp1ab D6468Y 1.00e+0 B.1.1.265
V7766 14460C>T synonymous_variant ORF1ab_pp1ab F4820F 1.00e+0 B.1.1.265
V8518 20406G>A synonymous_variant ORF1ab_pp1ab A6802A 1.00e+0 B.1.1.265
V3907 1447G>T missense_variant S V483F 1.00e+0 B.1.1.419
V4589 657G>T missense_variant ORF3a L219F 7.05e-1 B.1.1.419
V5088 55G>T stop_gained ORF8 E19* 7.05e-1 B.1.1.419
V561 1648C>T missense_variant ORF1ab_pp1a R550C 7.05e-1 B.1.1.419
V5614 1129G>T missense_variant N D377Y 7.05e-1 B.1.1.419
V7854 15177C>T synonymous_variant ORF1ab_pp1ab V5059V 7.05e-1 B.1.1.419
V8346 18871T>C synonymous_variant ORF1ab_pp1ab L6291L 7.05e-1 B.1.1.419
V4717 5C>T missense_variant M A2V 1.00e+0 B.1.1.435
V561 1648C>T missense_variant ORF1ab_pp1a R550C 1.00e+0 B.1.1.435
V3638 432_434delTTA disruptive_inframe_deletion S Y145del 1.00e+0 B.1.192
V9078 3444C>T synonymous_variant S F1148F 7.04e-1 B.1.192
V979 3322C>T missense_variant ORF1ab_pp1a H1108Y 1.00e+0 B.1.192
V355 856C>T missense_variant ORF1ab_pp1a P286S 1.00e+0 B.1.218
V6761 6525A>G synonymous_variant ORF1ab_pp1a L2175L 1.00e+0 B.1.218
V981 3337C>T missense_variant ORF1ab_pp1a H1113Y 1.00e+0 B.1.218
V1509 6362C>T missense_variant ORF1ab_pp1a T2121I 1.00e+0 B.1.408
V1926 9209C>T missense_variant ORF1ab_pp1a A3070V 7.06e-1 B.1.408
V3080 18244C>T missense_variant ORF1ab_pp1ab L6082F 6.29e-1 B.1.408
V5191 285G>T missense_variant ORF8 L95F 6.29e-1 B.1.408
V5916 418C>T synonymous_variant ORF1ab_pp1a L140L 8.15e-1 B.1.408
V7084 9165C>T synonymous_variant ORF1ab_pp1a I3055I 8.15e-1 B.1.408
V760 2441C>T missense_variant ORF1ab_pp1a T814I 8.15e-1 B.1.408
V8327 18696G>A synonymous_variant ORF1ab_pp1ab A6232A 6.29e-1 B.1.408
V9083 3474T>C synonymous_variant S N1158N 6.29e-1 B.1.408
V6125 1848C>T synonymous_variant ORF1ab_pp1a I616I 7.05e-1 B.1.618
V7726 14214C>T synonymous_variant ORF1ab_pp1ab Y4738Y 7.05e-1 B.1.618
V1326 5435C>A missense_variant ORF1ab_pp1a A1812D 8.62e-1 B.1.78
V4015 2031G>T missense_variant S Q677H 1.00e+0 B.1.78
V4537 514G>T missense_variant ORF3a G172C 1.00e+0 B.1.78
V5841 48C>T synonymous_variant ORF1ab_pp1a L16L 8.62e-1 B.1.78
V6569 5073T>C synonymous_variant ORF1ab_pp1a N1691N 1.00e+0 B.1.78
V6930 7938A>G synonymous_variant ORF1ab_pp1a V2646V 1.00e+0 B.1.78
V9520 105C>T synonymous_variant ORF8 D35D 1.00e+0 B.1.78
V7437 11895G>A synonymous_variant ORF1ab_pp1a E3965E -7.06e-1 BA.4.1.10
V3100 18387G>T missense_variant ORF1ab_pp1ab E6129D 1.00e+0 BA.4.1.3
V7465 12138C>T synonymous_variant ORF1ab_pp1a N4046N 1.00e+0 BA.4.1.3
V2754 15811G>T missense_variant ORF1ab_pp1ab D5271Y 1.00e+0 C.1.2
V4264 3687G>T missense_variant S M1229I 1.00e+0 C.1.2
V531 1555G>A missense_variant ORF1ab_pp1a G519S 7.06e-1 C.1.2
V8036 16623C>T synonymous_variant ORF1ab_pp1ab Y5541Y 7.06e-1 C.36.3.1
V3758 727G>T missense_variant S A243S 1.00e+0 P.4
V2018 10052A>G missense_variant ORF1ab_pp1a K3351R 8.36e-1 XAD
V197 254_259delTGGTTG disruptive_inframe_deletion ORF1ab_pp1a M85_E87delinsK 1.00e+0 XBC.1
V3327 20011G>T missense_variant ORF1ab_pp1ab D6671Y 1.00e+0 XBC.1
V4546 524C>T missense_variant ORF3a T175I 1.00e+0 XBC.1
V994 3382A>G missense_variant ORF1ab_pp1a I1128V 1.00e+0 XBC.1
V2321 12104C>T missense_variant ORF1ab_pp1a T4035I 1.00e+0 XE





Manual curation of mutation (7G>T)-related literature from PubMed

The pubmed.mineR and pubmed-mapper were utilized for extracting literature from PubMed, followed by manual filtering.
Note: PubMed: (COVID-19 [Title/Abstract] OR SARS-COV-2 [Title/Abstract]) AND (DNA mutation [Title/Abstract] OR Protein mutation-1 letter [Title/Abstract] OR Protein mutation-3 letter [Title/Abstract]).

DNA level Protein level Paper title Journal name Publication year Pubmed ID
7G>T E3* A close shave: How SARS-CoV-2 induces the loss of cilia J Cell Biol 2022 35695891
7G>T E3* A C-terminal glutamine recognition mechanism revealed by E3 ligase TRIM7 structures Nat Chem Biol 2022 35982226
7G>T E3* Adenovirus entry: Stability, uncoating, and nuclear import. Mol Microbiol 2022 35434852
7G>T E3* A dispersion-corrected DFT calculation on encapsulation of favipiravir drug used as antiviral against COVID-19 into carbon-, boron-, and aluminum-nitride nanotubes for optimal drug delivery systems combined with molecular docking simulations. Struct Chem 2023 37363043
7G>T E3* A high throughput screen for TMPRSS2 expression identifies FDA-approved and clinically advanced compounds that can limit SARS-CoV-2 entry Res Sq 2020 32818215
7G>T E3* A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry Nat Commun 2021 34162861
7G>T E3* An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2 J Phys Chem B 2021 33657325
7G>T E3* An expanded lexicon for the ubiquitin code Nat Rev Mol Cell Biol 2023 36284179
7G>T E3* Are H1 and H3 haplotypes of endothelial protein C receptor (PROCR) an important factor in contracting COVID-19? J Med Virol 2022 35710974
7G>T E3* Association of serum HDL-cholesterol and apolipoprotein A1 levels with risk of severe SARS-CoV-2 infection J Lipid Res 2021 33667465
7G>T E3* ATG5 provides host protection acting as a switch in the atg8ylation cascade between autophagy and secretion Dev Cell 2023 37054706
7G>T E3* Autonomous Synthesis of Functional, Permanently Phosphorylated Proteins for Defining the Interactome of Monomeric 14-3-3ζ. ACS Cent Sci 2023 37122473
7G>T E3* Bioinformatics analyses of significant genes, related pathways, and candidate diagnostic biomarkers and molecular targets in SARS-CoV-2/COVID-19. Gene Rep 2020 33553808
7G>T E3* BPOZ-2 is a negative regulator of the NLPR3 inflammasome contributing to SARS-CoV-2-induced hyperinflammation Front Cell Infect Microbiol 2023 36936774
7G>T E3* Comparative molecular docking analysis of the SARS CoV-2 Spike glycoprotein with the human ACE-2 receptors and thrombin Bioinformation 2020 32994678
7G>T E3* Comparative Multiplexed Interactomics of SARS-CoV-2 and Homologous Coronavirus Nonstructural Proteins Identifies Unique and Shared Host-Cell Dependencies ACS Infect Dis 2020 33263384
7G>T E3* Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies bioRxiv 2020 32699849
7G>T E3* Comprehensive landscape of the renin-angiotensin system in Pan-cancer: a potential downstream mediated mechanism of SARS-CoV-2 Int J Biol Sci 2021 34671200
7G>T E3* Computational search for drug repurposing to identify potential inhibitors against SARS-COV-2 using Molecular Docking, QTAIM and IQA methods in viral Spike protein - Human ACE2 interface. J Mol Struct 2021 33583954
7G>T E3* Contact residue contributions to interaction energies between SARS-CoV-1 spike proteins and human ACE2 receptors Sci Rep 2021 33441985
7G>T E3* Coronaviral PLpro proteases and the immunomodulatory roles of conjugated versus free Interferon Stimulated Gene product-15 (ISG15) Semin Cell Dev Biol 2022 35764457
7G>T E3* Correction To: The E3 ligase RNF5 restricts SARS-CoV-2 replication by targeting its envelope protein for degradation Signal Transduct Target Ther 2023 36849529
7G>T E3* Degradation of SARS-CoV-2 receptor ACE2 by the E3 ubiquitin ligase Skp2 in lung epithelial cells Front Med 2021 33511555
7G>T E3* DELTEX E3 ligases ubiquitylate ADP-ribosyl modification on protein substrates Sci Adv 2022 36197986
7G>T E3* Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge Front Immunol 2021 34603305
7G>T E3* Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms Sci Rep 2020 32848162
7G>T E3* E2UbcH5B-derived peptide ligands target HECT E3-E2 binding site and block the Ub-dependent SARS-CoV-2 egression: A computational study Comput Biol Med 2022 35751189
7G>T E3* E3 Ubiquitin Ligases: The Operators of the Ubiquitin Code That Regulates the RLR and cGAS-STING Pathways Int J Mol Sci 2022 36498930
7G>T E3* EGF domain peptide of Developmentally regulated endothelial locus1 facilitates gene expression of extracellularly applied plasmid DNA Biologicals 2022 35027253
7G>T E3* Elucidating the enhanced binding affinity of a double mutant SP-D with trimannose on the influenza A virus using molecular dynamics Comput Struct Biotechnol J 2022 36097510
7G>T E3* Environmental triggers for connective tissue disease: the case of COVID-19 associated with dermatomyositis-specific autoantibodies Curr Opin Rheumatol 2021 34506341
7G>T E3* E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition. Semin Immunol 2022 35227568
7G>T E3* Exploring the active compounds of traditional Mongolian medicine in intervention of novel coronavirus (COVID-19) based on molecular docking method J Funct Foods 2020 32421102
7G>T E3* Exploring the phytochemicals of Platycodon grandiflorus for TMPRSS2 inhibition in the search for SARS-CoV-2 entry inhibitors J King Saud Univ Sci 2022 35702062
7G>T E3* Generation of host-directed and virus-specific antivirals using targeted protein degradation promoted by small molecules and viral RNA mimics Cell Host Microbe 2023 37339625
7G>T E3* Glycan Epitopes and Potential Glycoside Antagonists of DC-SIGN Involved in COVID-19: In Silico Study Biomolecules 2021 34827585
7G>T E3* Heat shock protein 90 facilitates SARS-CoV-2 structural protein-mediated virion assembly and promotes virus-induced pyroptosis J Biol Chem 2023 37011862
7G>T E3* Heat Treatment Promotes Ubiquitin-Mediated Proteolysis of SARS-CoV-2 RNA Polymerase and Decreases Viral Load Research (Wash D C) 2022 35321260
7G>T E3* HERC5 and the ISGylation Pathway: Critical Modulators of the Antiviral Immune Response Viruses 2021 34207696
7G>T E3* Host E3 ligase HUWE1 attenuates the proapoptotic activity of the MERS-CoV accessory protein ORF3 by promoting its ubiquitin-dependent degradation J Biol Chem 2022 35032548
7G>T E3* Identification of tuna protein-derived peptides as potent SARS-CoV-2 inhibitors via molecular docking and molecular dynamic simulation Food Chem 2021 33092925
7G>T E3* Identifying compounds that prevent the binding of the SARS-CoV-2 S-protein to ACE2 Comput Biol Med 2021 34358993
7G>T E3* Implementation of a unique mass casualty and emergency preparedness longitudinal learning experience for postgraduate year 2 pharmacy residents Curr Pharm Teach Learn 2022 35914853
7G>T E3* [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs] Biol Aujourdhui 2021 34397373
7G>T E3* Inhibition of HECT E3 ligases as potential therapy for COVID-19 Cell Death Dis 2021 33762578
7G>T E3* Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19) Mini Rev Med Chem 2021 33208074
7G>T E3* In silico, in vitro screening of plant extracts for anti-SARS-CoV-2 activity and evaluation of their acute and sub-acute toxicity. Phytomed Plus 2022 35403091
7G>T E3* K63 ubiquitination in immune signaling Trends Immunol 2022 35033428
7G>T E3* Long-covid cognitive impairment: Cognitive assessment and apolipoprotein E (APOE) genotyping correlation in a Brazilian cohort Front Psychiatry 2022 36046159
7G>T E3* MARCH8 Targets Cytoplasmic Lysine Residues of Various Viral Envelope Glycoproteins Microbiol Spectr 2022 35019698
7G>T E3* MDM2-Mediated Ubiquitination of Angiotensin-Converting Enzyme 2 Contributes to the Development of Pulmonary Arterial Hypertension Circulation 2020 32755395
7G>T E3* Mechanism of Viral Glycoprotein Targeting by Membrane-associated-RING-CH Proteins bioRxiv 2021 33532773
7G>T E3* Mechanism of Viral Glycoprotein Targeting by Membrane-Associated RING-CH Proteins mBio 2021 33727347
7G>T E3* Missense variants in human ACE2 strongly affect binding to SARS-CoV-2 Spike providing a mechanism for ACE2 mediated genetic risk in Covid-19: A case study in affinity predictions of interface variants PLoS Comput Biol 2022 35235558
7G>T E3* Modulation of lysosomal function as a therapeutic approach for coronaviral infections Res Sq 2021 34013250
7G>T E3* Monkeypox virus: phylogenomics, host-pathogen interactome and mutational cascade. Microb Genom 2023 37043267
7G>T E3* mTOR inhibition and p53 activation, microRNAs: The possible therapy against pandemic COVID-19. Gene Rep 2020 32835132
7G>T E3* Multiomics approach reveals the ubiquitination-specific processes hijacked by SARS-CoV-2 Signal Transduct Target Ther 2022 36071039
7G>T E3* N439K Variant in Spike Protein Alter the Infection Efficiency and Antigenicity of SARS-CoV-2 Based on Molecular Dynamics Simulation Front Cell Dev Biol 2021 34414185
7G>T E3* Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment Alzheimers Res Ther 2021 34108016
7G>T E3* Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment bioRxiv 2021 33791705
7G>T E3* ORF10-Cullin-2-ZYG11B complex is not required for SARS-CoV-2 infection Proc Natl Acad Sci U S A 2021 33827988
7G>T E3* P054 IBD Associated Surveillance Dysplasia Program: New Integrated Model: Audit, Summary, Future Directions and Literature Review. Am J Gastroenterol 2021 37461972
7G>T E3* Point-specific interactions of isovitexin with the neighboring amino acid residues of the hACE2 receptor as a targeted therapeutic agent in suppressing the SARS-CoV-2 influx mechanism J Adv Vet Anim Res 2022 35891654
7G>T E3* Potential antiviral effects of pantethine against SARS-CoV-2 Sci Rep 2023 36754974
7G>T E3* Potential targets of severe acute respiratory syndrome coronavirus 2 of clinical drug fluvoxamine: Docking and molecular dynamics studies to elucidate viral action Cell Biochem Funct 2023 36478589
7G>T E3* Protein degradation: a novel computational approach to design protein degrader probes for main protease of SARS-CoV-2 J Biomol Struct Dyn 2022 34328382
7G>T E3* Proteomic Signature of Host Response to SARS-CoV-2 Infection in the Nasopharynx Mol Cell Proteomics 2021 34400346
7G>T E3* Qing-Fei-Pai-Du decoction and wogonoside exert anti-inflammatory action through down-regulating USP14 to promote the degradation of activating transcription factor 2 FASEB J 2021 34436790
7G>T E3* Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2 Bioconjug Chem 2021 33356169
7G>T E3* Role of E3 ubiquitin ligases and deubiquitinating enzymes in SARS-CoV-2 infection Front Cell Infect Microbiol 2023 37360529
7G>T E3* SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response mBio 2021 34544279
7G>T E3* SARS-CoV-2 ORF10 impairs cilia by enhancing CUL2ZYG11B activity J Cell Biol 2022 35674692
7G>T E3* SARS-CoV-2 spike protein enhances MAP4K3/GLK-induced ACE2 stability in COVID-19 EMBO Mol Med 2022 35894122
7G>T E3* SARS-CoV-2 viral protein ORF3A injures renal tubules by interacting with TRIM59 to induce STAT3 activation Mol Ther 2023 36523164
7G>T E3* Social distancing and supply disruptions in a pandemic Quant Econom 2022 35942438
7G>T E3* Spatial and temporal roles of SARS-CoV PLpro -A snapshot FASEB J 2021 33368679
7G>T E3* State fragility and the coronavirus disease 2019 (COVID-19) pandemic: an ecologic analysis of data from 146 countries Glob Health J 2021 33585049
7G>T E3* Structural-based design of HD-TAC7 PROteolysis TArgeting chimeras (PROTACs) candidate transformations to abrogate SARS-CoV-2 infection J Biomol Struct Dyn 2023 36841549
7G>T E3* Structural insights into ORF10 recognition by ZYG11B Biochem Biophys Res Commun 2022 35636250
7G>T E3* Structural modeling of protein ensembles between E3 RING ligases and SARS-CoV-2: The role of zinc binding domains J Trace Elem Med Biol 2023 36209710
7G>T E3* Suppression of ACE2 SUMOylation protects against SARS-CoV-2 infection through TOLLIP-mediated selective autophagy Nat Commun 2022 36057605
7G>T E3* Susceptibility of Dog, Hamster, and Mouse Cells to the Replication-Competent Adenovirus 11p E1/E3 Green Fluorescence Protein Vector Has Implications for the Selection of Animal Vaccine Models. Front Microbiol 2021 34777270
7G>T E3* Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions Commun Biol 2020 33230174
7G>T E3* The Deubiquitinase USP29 Promotes SARS-CoV-2 Virulence by Preventing Proteasome Degradation of ORF9b mBio 2022 35638730
7G>T E3* The E3 ligase RNF5 restricts SARS-CoV-2 replication by targeting its envelope protein for degradation Signal Transduct Target Ther 2023 36737599
7G>T E3* The E3 Ubiquitin Ligase RNF5 Facilitates SARS-CoV-2 Membrane Protein-Mediated Virion Release mBio 2021 35100873
7G>T E3* The Human Adenovirus Type 2 Transcriptome: An Amazing Complexity of Alternatively Spliced mRNAs J Virol 2021 33239457
7G>T E3* The human E3 ligase RNF185 is a regulator of the SARS-CoV-2 envelope protein iScience 2023 37095859
7G>T E3* The Mitochondrial Outer Membrane Protein Tom70-Mediator in Protein Traffic, Membrane Contact Sites and Innate Immunity. Int J Mol Sci 2020 33019591
7G>T E3* The Multifaceted Role of the Ubiquitin Proteasome System in Pathogenesis and Diseases Biomolecules 2022 35883481
7G>T E3* The Nucleocapsid Proteins of SARS-CoV-2 and Its Close Relative Bat Coronavirus RaTG13 Are Capable of Inhibiting PKR- and RNase L-Mediated Antiviral Pathways Microbiol Spectr 2023 37154717
7G>T E3* The RNA helicase DHX16 recognizes specific viral RNA to trigger RIG-I-dependent innate antiviral immunity Cell Rep 2022 35263596
7G>T E3* The Src-ZNRF1 axis controls TLR3 trafficking and interferon responses to limit lung barrier damage J Exp Med 2023 37158982
7G>T E3* The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing Heliyon 2021 33688584
7G>T E3* TRIM21 promotes ubiquitination of SARS-CoV-2 nucleocapsid protein to regulate innate immunity J Med Virol 2023 37185839
7G>T E3* Ubiquitination of SARS-CoV-2 NSP6 and ORF7a Facilitates NF-κB Activation mBio 2022 35856559
7G>T E3* UBR5 Acts as an Antiviral Host Factor against MERS-CoV via Promoting Ubiquitination and Degradation of ORF4b J Virol 2022 35980206
7G>T E3* Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment Vaccine 2022 35715352
7G>T E3* VANGL2 inhibits antiviral IFN-I signaling by targeting TBK1 for autophagic degradation Sci Adv 2023 37352355
7G>T E3* Viral Evasion of RIG-I-Like Receptor-Mediated Immunity through Dysregulation of Ubiquitination and ISGylation Viruses 2021 33530371